Primary dysmenorrhoea is painful menstrual cramps of uterine origin during menstruation without any identifiable pathological lesion. It is commonly seen in menstruating and lasting 12-24 h. Its prevalence is wide, as more than 70% of teenagers and 30-50% of menstruating women suffer from varying degree of discomfort. Tibbe-e-Unani claims to possess safe and effective therapeutic substances which are commonly prescribed in the management of primary dysmenorrhoea (Usr-e-Tams Ibtedayee), but despite being used in the treatment successfully, most of them have yet not been studied scientifically. Therefore, an attempt has been made in the present study to evaluate a single Unani drug Tukhm-e-Sambhalu (Vitex negundo) on 30 patients for its efficacy in primary dysmenorrhoea. The patients were administered test drug in powder form (5 g), by oral rout, twice a day for 7 days, starting 2 days before the onset of menstruation up to 5^th day of menses, for three consecutive cycles. The important clinical features like pain in suprapubic region, pain in thigh, backache and headache were significantly reduced in patients treated with test drug. Thus, findings of this study suggested that Tukhm-e-Sambhalu is safe and effective in ameliorating the disease primary dysmenorrhoea.

中文翻译：

---

Tukhm-e-Sambhalu（Vitex negundo Linn。种子）在Usr-e-Tams Ibtedayee（原发性痛经）中的临床评价

原发性痛经是月经期间子宫痛性子宫痛，无任何可识别的病理性病变。通常在经期和持续12-24小时内见到。其患病率很高，超过70％的青少年和30-50％的经期女性遭受不同程度的不适。Tibbe-e-Unani声称拥有治疗原发性痛经的常用安全且有效的治疗药物（Usr-e-Tams Ibtedayee），但尽管已成功使用该治疗方法，但大多数尚未进行科学研究。因此，在本研究中已尝试评估单一的Unani药物Tukhm-e-Sambhalu（Vitex negundo）治疗30例原发性痛经的疗效。从月经开始前两天开始直至月经^第5天，通过口服溃烂，每天两次给患者服用粉末形式的测试药物（5 g），共7天，连续三个周期。受试药物治疗的患者的重要临床特征（如耻骨上区域的疼痛，大腿的疼痛，腰酸和头痛）显着降低。因此，这项研究的结果表明，Tukhm-e-Sambhalu在缓解原发性痛经方面是安全有效的。